Probe Into Novo's Ozempic and Possible Eye Disorder Risk Intensifies After Studies

The potential link between Novo Nordisk's Ozempic and a rare eye disorder, non-arteritic anterior ischemic optic neuropathy (NAION), has gained attention following recent studies from the University of Southern Denmark and other researchers. These studies suggest a slight increase in the risk of NAION among users of Ozempic, which contains the active ingredient semaglutide, although the absolute risk remains low[1][2]. NAION, characterized by impaired blood flow to the optic nerve leading to sudden vision loss, predominantly affects individuals over 50[1]. The Danish Medicines Agency has flagged this potential risk and has sought a review by European Pharmacovigilance Risk Assessment Committee, although Novo Nordisk maintains their stance on the favorable benefit-risk profile of semaglutide[2].